Pan Am Cancer Treatment Centers Announcement of ImmunoMax

SAN DIEGO - Aug. 19, 2015 - PRLog -- Pan Am Cancer Treatment Centers Announces Availability of ImmunoMax Natural Killer Cell Activating Immunotherapy for Advanced Cancer Patients

The Pan Am Cancer Treatment Centers, an institution dedicated to providing cutting-edge immunotherapies to cancer patients in an accelerated manner, announced today availability of ImmunoMax to advanced cancer patients that meet inclusion criteria.

ImmunoMax is a pharmaceutical grade polysaccharide of plant origin that has been demonstrated to stimulate natural killer cells[1]. ImmunoMax has been on the market in Russia for 12 years for treatment of viral and bacterial infections, with reports demonstrating reduction of PSA in prostate cancer patients[2].

“It is well known that many cancer patients have a suppressed natural killer cell activity as compared to healthy controls, studies have demonstrated that patients with low natural killer cell activity have a poorer prognosis as compared to patients with higher natural killer cell activity[3],[4],[5].” Said Dr. Javier Lopez, Chief Executive Officer of the Pan Am Cancer Treatment Centers. “Efficacy of numerous cancer therapies offered by oncologists such as Herceptin[6],[7], Rituximab[8], and Cetuximab[9], have been shown to depend on activity of the patient’s natural killer cell activity.  It is conceivable that utilization of ImmunoMax by itself, or in combination with existing therapies may be of benefit to cancer patients.”

In 2015, a peer-reviewed paper authored by scientists at the University of California Irvine, the Institute for Molecular Medicine, and the Gamaley Research Institute of the Russian Ministry of Health demonstrated that ImmunoMax activates not only natural killer cells but also dendritic cells.  Additionally, the paper demonstrated profound inhibition of breast cancer growth and metastasis in a higher aggressive animal model [10].

“In an age where the promise of cancer immunotherapy has the medical community electrified with positive results from trials using checkpoint inhibitors and CAR-T cells, it is important to remember that the innate immune system is critical both to initiation of antitumor immunity, as well as maintenance of the immune response and establishment of immunological memory.” Said Dr. Selva Pallares “We are proud to begin offering, to patients that fit the criteria, access to ImmunoMax, which in our opinion is a highly promising immune stimulatory therapeutic.

Contact information:
Giselle Paredes
Patient Services Coordinator
Phone: (619) 735-9581
RELATED LINKS
http://cancerimmunotherapy.mx/web

Twitter: @exosome

[1] http://www.gepon.ru/deutsch/data/arts/Imm_prosp_eng.pdf

[2] Ataullakhanov et al. Immunomax^R therapy to obtain relief in papilloma virus infections, prostatitis, and prostate carcinoma. J Mens Health. 2010;7:396–405.

[3] http://www.ncbi.nlm.nih.gov/pubmed/12060116/

[4] http://www.ncbi.nlm.nih.gov/pubmed/16273350

[5] http://www.ncbi.nlm.nih.gov/pubmed/12900537

[6] http://www.ncbi.nlm.nih.gov/pubmed/18485193

[7] http://www.ncbi.nlm.nih.gov/pubmed/16404427/

[8] http://www.ncbi.nlm.nih.gov/pubmed/23613524

[9] http://www.ncbi.nlm.nih.gov/pubmed/20591136

[10] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261251/pdf/12967_2014_Article_322.pdf